Hyperkalemia in hemodialysis patients
Conditions
Interventions
Experimental group:Sodium Zirconium Cyclosilicate
Control group:Insulin and glucose
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Subject signs informed consent; 2.Female or male, patients >= 18 years of age; 3.Maintenance hemodialysis patients who have been on dialysis for more than three months ; 4.Serum potassium is between 5.5 mmol/L and 6.5 mmol/L .
Exclusion criteria
Exclusion criteria: 1.During screening, hemoglobin14g/dL white blood cells > 20x10^9/L serum calcium < 8.2mg/dL (corrected calcium < 8.0mg/dL) or severe acidosis (serum bicarbonate <= 16mmol/l) ; 2.Have used lactulose, rifaximin, other non-absorbable antibiotics, sodium zirconium cyclic silicate, calcium polystyrene sulfonate, or patronome within 7 days before randomization ; 3.Severe disease, myocardial infarction, acute coronary syndrome (New York Heart Function Classification (NYHA) iii or higher), stroke, seizure or thromboembolic events occurred within 12 weeks before randomization; 4.Patients who cannot take medicines orally; 5.Known allergy or history of allergy to sodium zirconium cyclosilicate or its components; 6.There are contraindications to the use of insulin; 7.Maintenance hemodialysis patients with residual urine volume; 8.Planning or participating in other clinical studies (1 month before screening); 9.The investigator judges that there is a safety risk to the patient or there are other unsuitable conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum potassium; | — |
Countries
China
Contacts
Public ContactLiu Zhangsuo; Wang Pei
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed